In this study, we showed that PEITC inhibited the growth of prostate cancers expressing different hotspot p53 mutants, p53R175H and p53R248W, with differential potencies, by restoring transactivation functions to both mutants, suggesting that PEITC acts in mutation type-dependent manner. Here, TP53 is linked to prostate carcinoma.